Stock Market Reviews

ABBV (AbbVie Inc.) News

Get the latest news, insights, and market updates on ABBV (AbbVie Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• AbbVie Partners with Award-Winning Filmmaker on Film About the Dynamic and Resilient Lives of Those Living with Blood Cancer
  AbbVie (NYSE: ABBV) announced today the launch of Second Winds, a new short film that captures the powerful, deeply personal journeys of three people living with chronic lymphoma leukemia (CLL), a common type of blood cancer effecting hundreds of thousands of people in the United States.1,2 Each person's dynamic story reveals how facing a life-changing diagnosis can bring clarity and purpose, sparking a renewed commitment to staying active and embracing what truly matters in their lives.
  Nov 14, 2025 - $ABBV
• AbbVie (ABBV): Evaluating Valuation Following Strong Results, Dividend Hike, and Key Strategic Shifts
  AbbVie (ABBV) is back in the spotlight after announcing strong quarterly results and a 6% dividend increase. The company also made waves by shifting strategy away from its Calico Life Sciences partnership and updating investors on several fronts. See our latest analysis for AbbVie. AbbVie shares have outpaced much of the market lately, supported by upbeat earnings, a hefty dividend increase, and high-profile strategic refocusing. With a 29% year-to-date share price return and a standout 46%...
  Nov 14, 2025 - $ABBV
• Is that pharma influencer human or AI?
  Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.
  Nov 14, 2025 - $ABBV
• IRWD Rises 110% in a Month: Should You Buy, Sell or Hold the Stock?
  Ironwood's 110% monthly surge follows upbeat third-quarter results and raised 2025 outlook, powered by increasing Linzess demand.
  Nov 13, 2025 - $ABBV
• Stock Market News for Nov 13, 2025
  Wall Street closed mixed on Wednesday, pulled up by healthcare and financial stocks.
  Nov 13, 2025 - $ABBV
• UCB’s Bimzelx and AbbVie’s Rinvoq Lead in EU5 Psoriatic Arthritis, Ankylosing Spondylitis, and Non-Radiographic Axial Spondyloarthritis Growth
  New insights from Spherix Global Insights reveal strong rheumatologist anticipation for next-generation oral and multi-pathway innovations, including Sotyktu, icotrokinra, and sonelokimab.Exton, PA, Nov. 13, 2025 (GLOBE NEWSWIRE) -- The 2025 Market Dynamix™: Psoriatic Arthritis and Ankylosing Spondylitis/Non-Radiographic Axial Spondyloarthritis (EU5) studies from Spherix Global Insights reveal a rapidly evolving treatment landscape, as rheumatologists expand use of next-generation IL-17 and JAK
  Nov 13, 2025 - $ABBV
• Robert Bruce's Strategic Moves: AT&T Inc. Sees a -1.41% Portfolio Impact
  Insightful Analysis of Robert Bruce (Trades, Portfolio)'s Third Quarter 2025 13F Filing
  Nov 13, 2025 - $ABBV
• Shine a Light on Healthcare ETFs Amid National Alzheimer's Awareness Month
  As National Alzheimer's Awareness Month spotlights new treatments, healthcare ETFs like XLV and VHT might gain fresh investor appeal.
  Nov 13, 2025 - $ABBV
• Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls
  Nov 13, 2025 - $ABBV
• AbbVie Announces 20 Recipients of Migraine Career Catalyst Award™
  AbbVie (NYSE: ABBV) today announced the 20 recipients of its second annual AbbVie Migraine Career Catalyst Award™ contest, an initiative that helps people living with migraine pursue their career and professional development goals. Each winner received $2,500 in financial support to invest in opportunities that advance their aspirations, from continued education and training to creating healthier, more supportive work environments.
  Nov 13, 2025 - $ABBV